证券代码：600873 证券简称：梅花生物 公告编号：2026-006 梅花生物科技集团股份有限公司 关于2026年员工持股计划实施进展的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 梅花生物科技集团股份有限公司（以下简称"公司"）分别于 2025 年 12 月 11 日、2025 年 12 月 29 日召开第十届董事会第二十三次会议和 2025 年第二次临 时股东大会，审议通过《关于公司 2026 年员工持股计划（草案）及其摘要的议 案》《关于公司 2026 年员工持股计划管理办法的议案》《关于提请股东大会授权 董事会全权办理公司员工持股计划相关事项的议案》，具体内容详见公司于 2025 年 12 月 12 日、2025 年 12 月 30 日在上海证券交易所网站（http://www.sse.com.cn） 上披露的相关公告。 根据中国证监会《关于上市公司实施员工持股计划试点的指导意见》及《上 海证券交易所上市公司自律监管指引第 1 号—规范运作》等要求，现将公司 2026 年员工持股计划实施进展情况公告如下： 1. ...

Group 1 - The core point of the article highlights the performance of the Agricultural and Animal Husbandry ETF managed by Jianxin Fund, which opened at 0.904 yuan and experienced a slight decline of 0.33% [1] - The ETF's major holdings include Cangge Mining, which rose by 3.34%, and Yilake Co., which increased by 2.82%, while other stocks like Muyuan Foods and New Hope saw minor declines [1] - Since its inception on July 21, 2022, the ETF has reported a return of -9.46%, with a recent one-month return of 3.27% [1] Group 2 - The ETF's performance benchmark is the CSI Agricultural and Animal Husbandry Theme Index return [1] - The fund manager is Jianxin Fund Management Co., Ltd., and the fund manager is Gong Jiajia [1]

Core Viewpoint - The company aims to focus on high-quality growth in its core business and aspires to become a leading enterprise in synthetic biology, positioning itself as a competitive industry leader in the amino acid sector [1] Group 1: Strategic Focus - The company is committed to becoming a "lighthouse factory" in the amino acid industry, emphasizing the importance of technological and management leadership as dual drivers for growth [1] - The company plans to enhance its competitive edge by advancing research and development, supply chain, production, sales, and various functional departments simultaneously [1] Group 2: Corporate Values - The company emphasizes a commitment to creating and sharing value, maintaining a customer-centric approach, and upholding integrity as fundamental principles [1]

Group 1 - The core viewpoint of the article is that Meihua Biological has announced the purchase price for its 2026 employee stock ownership plan will be based on the company's stock market price [2] Group 2 - The announcement was made on January 20, during an interaction with investors on the platform [2]

证券日报网讯 1月20日，梅花生物在互动平台回答投资者提问时表示，公司整体海外收入占比约30%； 公司在欧盟地区的销售以直销为主。 （文章来源：证券日报） ...

Core Insights - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative sector, which is seen as a new growth point that can help optimize industrial structures and transform economic models [1]. Group 1: Current State and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current status and trends in biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this field [5]. Group 2: Policy Landscape - The white paper discusses major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. Group 3: Industry Map and Applications - It provides a comprehensive map of the Chinese biomanufacturing industry and analyzes the industry chain along with key application directions, including biomanufacturing in pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The report identifies ten leading enterprises in the Chinese biomanufacturing sector, detailing their contributions and roles within the industry [5][6]. Group 5: Company Strategies - It outlines the synthetic biology strategies of 15 listed companies, summarizing their development approaches and corresponding popular products [5][6]. Group 6: Investment and Challenges - The white paper reviews the investment and financing situation in domestic synthetic biology from 2024 to mid-2025 and discusses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [5][6].

Group 1 - The core viewpoint of the articles highlights the positive trend in pig prices driven by the consumption peak season, with the average price of lean pigs reaching 12.49 CNY/kg, a 2.6% increase month-on-month [1] - The stock performance of the livestock breeding index shows mixed results, with leading stocks like Ruisheng Biological rising by 9.91% and the Livestock ETF priced at 0.68 CNY [1] - The overall pig farming sector is experiencing a "tug-of-war" state, where companies with cost advantages are more resilient in competition [1] Group 2 - According to Huaxi Securities, the average price of external three yuan pigs reached 12.7 CNY/kg, a week-on-week increase of 1.26%, indicating a steady rise in pig prices [2] - As of the end of October, the number of breeding sows in China was 39.9 million, a decrease of 1.1% month-on-month, reflecting ongoing adjustments in pig production capacity [2] - The self-breeding and external purchasing pig farming models have turned profitable, with profits of 7.39 CNY/head and 2.31 CNY/head respectively [2] Group 3 - The CSI Livestock Breeding Index (930707) includes companies involved in livestock feed, veterinary drugs, and livestock farming, reflecting the overall performance of listed companies in the livestock sector [2] - The top ten weighted stocks in the CSI Livestock Breeding Index account for 67.66% of the index, with major companies including Muyuan Foods, Haida Group, and Wens Foodstuffs [2]

Core Viewpoint - Meihua Biological Technology Group Co., Ltd. has shown a positive stock performance with a 6.42% increase year-to-date and a significant rise in net profit, indicating potential growth in the amino acid market [1][2]. Company Overview - Meihua Biological, established on February 9, 1995, and listed on February 17, 1995, is located in Langfang, Hebei Province. The company specializes in the research, production, and sales of amino acid products [1]. - The main revenue sources are feed amino acids (46.09%), flavor enhancers (29.04%), by-products (15.38%), other products (7.47%), and pharmaceutical amino acids (2.01%) [1]. Financial Performance - For the period from January to September 2025, Meihua Biological reported a revenue of 18.215 billion yuan, a year-on-year decrease of 2.49%, while net profit attributable to shareholders increased by 51.61% to 3.025 billion yuan [2]. - The company has distributed a total of 12.047 billion yuan in dividends since its A-share listing, with 4.075 billion yuan distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 13.10% to 66,700, while the average number of circulating shares per person decreased by 13.09% to 42,058 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 18.336 million shares, and new entrants like Guotai CSI Livestock Breeding ETF and Southern S&P China A-share Large Cap Dividend Low Volatility 50 ETF [3].

Group 1 - The company is integrating its acquired overseas business according to its established plan, with specific performance details available in regular reports [1] - The acquired assets primarily consist of pharmaceutical amino acid products, including arginine and histidine, for which domestic production bases have initiated project preparations [1]

Core Insights - The article presents the top 20 stocks in the S&P China A-Share Dividend Opportunity Index (CSPSADRP) based on their daily and year-to-date performance as of January 15, 2026, highlighting significant gainers and their dividend yields [1][5]. Group 1: Stock Performance - The top performer is Aotewi (688516.SH) with a daily increase of 8.15% and a year-to-date increase of 32.30%, along with a dividend yield of 3.80% [1][5]. - Weichai Power (000338.SZ) ranks second with a daily rise of 4.18% and a year-to-date increase of 17.44%, offering a dividend yield of 3.62% [1][5]. - Action Education (605098.SH) follows with a daily gain of 4.01% and a year-to-date increase of 11.71%, featuring a dividend yield of 5.02% [1][5]. Group 2: Dividend Yields - The highest dividend yield among the top 20 stocks is from Jichuan Pharmaceutical (600566.SH) at 7.99%, with a daily increase of 1.57% and a year-to-date increase of 0.84% [1][5]. - Other notable dividend yields include Oppein Home (603833.SH) at 6.85% and Qianjiang Motorcycle (000913.SZ) at 5.67% [1][5]. Group 3: Market Trends - The article notes the formation of a MACD golden cross signal, indicating a positive trend in the stock market, particularly for the highlighted stocks [4][8].